System for activating neurons in the human eye and brain
The tACS system with ergonomically designed applicators and temple-placed electrodes addresses the inadequacies of existing treatments by enhancing blood flow and neural synchronization, effectively improving visual and cognitive functions in long-term COVID patients.
Patent Information
- Application Number
- JP2024531147
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-14
- Filing Date
- 2022-02-16
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for visual and cognitive impairments, particularly in long-term COVID patients, are inadequate, with existing neuromodulation systems being uncomfortable, difficult to use, and lacking reproducibility for home therapy.
A non-invasive transcranial alternating current pulse stimulation (tACS) system with ergonomically designed applicators and electrodes placed at the temples, combined with a data processing control unit, provides patient-specific stimulation sequences and includes NIR spectroscopy for blood flow regulation, optimizing treatment efficacy.
The system effectively improves blood flow and synchronizes neural networks, leading to partial recovery of visual field and cognitive functions in patients, with measurable improvements in vascular dynamics and reduced stress.
Smart Images

Figure 2024541493000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates according to claim 1 to a system for activating nerve cells in the human eye and brain by neuromodulation, in particular non-invasive application of microcurrents to the head, more particularly non-invasive transcranial alternating current pulse stimulation (tACS), in order to enhance residual vision in the presence of visual field defects and to reduce or correct other visual or cognitive deficits, the system comprising an applicator for inducing energy flow to said eye and brain, stimulating blood flow and activating nerve cells, in particular retinal ganglion cells, an impulse generator for generating electrical or magnetic stimulation signals, and a data processing and control unit for applying patient-specific stimulation signal sequences, the applicator comprising, for example, at least two electrodes which can be brought into contact with the subject's head, in which the stimulation electrodes, in particular exchangeable electrodes, are preferably fixed to the applicator so as to rest or abut on the left and right of the eye in the region of the temples of the patient's head. [Background technology]
[0002] Visual field defects have been considered irreversible because the nerve cells of the retina, optic nerve, and brain cannot regenerate. However, it has been shown that the brain, which evaluates and interprets retinal signals, can permanently amplify residual signals through certain mechanisms, allowing partial recovery of visual field defects. In addition, there are also nerve cells in the retina that reduce their function after pathological events and "death". This is because these nerve cells can no longer send neural signals without dying.
[0003] As experience has shown that almost all patients still have residual vision, i.e. the so-called residual vision, it has been proposed to strengthen the residual vision by reactivating "silent" nerve cells and improving synaptic transmission. Clinical studies have shown the success of treatment methods such as visual training or alternating current stimulation. In alternating current treatment, the entire retina and parts of the brain are activated and synchronized. The majority of patients respond well to the above forms of treatment. Physiological studies of the mechanism of alternating current using EEG and fMRI have shown large local and global changes in blood flow and reorganization of neural networks in the brain. Local activation of nerve cells occurs in the visual system of the eye and the brain through a global reorganization of the neural network. Not only the eye but also the brain is very important for visual rehabilitation in ophthalmology, since residual vision can be strengthened by reactivating nerve cells and regulating neuroplasticity.
[0004] For some time now, brain adaptability, also known as plasticity, has been used in ophthalmology: the method of neuromodulation with weak alternating currents can be used to enhance partially damaged visual function through the process of neuroplasticity.
[0005] Recently, a method using alternating current pulses to improve blood flow and resynchronize brain network activity has been tested in patients with hemianopia. Here, alternating current is administered non-invasively for several days in prescribed sessions using special electrodes worn on the forehead. The alternating current flows from the electrodes to the eye, where it stimulates retinal ganglion cells to fire at a prescribed frequency with the goal of resynchronizing the brain network. Damage to the optic nerve leads to disorganization of functional networks in the brain, which is reflected by neurophysiological desynchronization in the EEG. Treatment using alternating current can significantly improve this condition by improving blood circulation and resynchronizing brain network activity.
[0006] However, visual resynchronization performance varies greatly from person to person and depends on a wide range of factors.
[0007] In addition to optimizing the stimulation impulse, it is also important to avoid causing too much stress to the patient, at least during the treatment. For this purpose, it is necessary to create an optimized form of stimulation electrodes, including the technical means for holding these electrodes on the patient's head. Therefore, an applicator must be created that is ergonomically optimal, particularly suitable for the treatment, and meets all the requirements.
[0008] It is also essential to optimize stimulation so that therapeutic success is maintained for as long as possible beyond the stimulation period.
[0009] With regard to the prior art, reference is made to EP 1 603 633 which shows a special mounting for the stimulation device at a desired position on the patient's head, in which case the adjustment structure is made of a deformable material which allows the device to adapt to the contours of the patient's head.
[0010] Fastening devices or arrangements for contacting the stimulation electrodes are also disclosed in EP1708787 and EP1734877.
[0011] With regard to prior art in brain stimulation with additional control of blood flow behaviour in adjacent vessels, attention is directed to WO 2011 / 106660 and WO 2016 / 115392.
[0012] WO 2011 / 106660 focuses on the recognition of the effect of stimulation, in particular on simultaneous stimulation and the recording of the stimulation effect in real time. For this purpose, functional near-infrared spectroscopy is used non-invasively during stimulation. Functional near-infrared spectroscopy is used to measure the oxygenation state of hemoglobin.
[0013] WO 216 / 115392 relates to an apparatus and method for determining neurovascular reactivity using stimulation of the neurovascular system and simultaneous recording of the neurohemodynamic response thereto.
[0014] With regard to the various possibilities for forming stimulation electrodes and corresponding applicators, attention is directed to the prior art which is briefly outlined below.
[0015] US Patent No. 5,522,864 discloses a headband-like electrode holder. A first electrode is attached to the patient's closed eyelids. A second electrode is fixed in the headband. A third electrode is attached to the neck area. This type of electrode formation, especially the attachment of the electrode to the closed eyelids, is perceived as uncomfortable for the patient and exposes the patient to negative stress for the success of the treatment.
[0016] In the surrounding patent family of EP 3013414 showing a stimulation device for transcutaneous electrical stimulation, several electrodes are also fixed at positions clearly separated from each other. A first electrode is attached to the patient's forehead area. A second electrode is placed on the patient's neck or shoulder. This electrode arrangement is difficult to individualize and can only be optimally positioned by the patient with the help of a third party, which is a considerable disadvantage for home treatment.
[0017] EP 3349844 deals with treatment with microcurrents. For this, punctate stimulating electrodes are applied above and below the eye in the eyelid area. Direct placement in such sensitive eye areas is uncomfortable for many patients, especially since the electrodes are relatively small and therefore do not provide sufficient current strength. Even very low currents can be felt, but they are not therapeutically effective enough. This type of electrode design is not widely used, since human skin is very sensitive to stimulation, especially in the upper and lower eye areas.
[0018] EP 2981326 shows a headset-like arrangement for electrical stimulation of the skin surface of the head.
[0019] DE 102011055844 discloses a glasses-like carrier for stimulation electrodes with an additional nose support similar to that of typical glasses. The electrodes are designed to be removable, i.e. replaceable. However, this arrangement uses hair electrodes that are located directly on the cornea of the eye, which entails the risk of corneal damage.
[0020] In EP 2 651 504 a headband is provided as an electrode carrier for neural stimulation, the headband being applied to the patient's head region and corresponding electrodes being symmetrically attached to the occipital region of the patient's head. There are also electrical connections for connecting the electrodes to a separate impulse generator.
[0021] The device according to US 2006 / 129207 for electrical stimulation of ganglion cells is also based on a spectacle-like structure with electrodes connected to the subject's eyelids. Although the support is intended to minimize uncomfortable pressure on the eyelids, this brings the drawback that the contact resistance between the electrodes and the subject's skin is not always clearly reproducible.
[0022] In summary, the prior art shows a large number of different applicators for electrical stimulation, including local activation of the eye and brain, and most of the known applicators are not suitable for home therapy, i.e. for reproducible, simple and risk-free application by the patient without medical or physician assistance.
[0023] There are currently no known effective therapeutic measures or systems to treat COVID disease or vaccination patients or subsequent patients who suffer from long-term vision or cognitive deficits (such as impaired attention, memory, speech comprehension or fatigue).
[0024] It is recognized that COVID infection causes circulatory disturbances that can lead to neurological dysfunction.
[0025] Many COVID patients are now reporting various functional complaints in the sense of a persistent state of illness. This also occurs in non-hospitalized individuals who initially had only mild COVID-19 symptoms that later develop into symptoms such as headache, chest pain, muscle pain, tingling and pins and needles, loss of smell, persistent cough, shortness of breath, palpitations or diarrhea, as well as abdominal pain, rash, fever, fatigue, forgetfulness and depression.
[0026] Long COVID patients also exhibit abnormalities in mood function and lower stress tolerance.
[0027] In addition to cognitive and emotional disorders, long COVID patients may also have visual problems. However, such problems tend to be benign and are rarely investigated, so they are not yet recognized by the patient or treating physician. However, as is evident from publications, not only do COVID patients have viral RNA and retinal vascular abnormalities in the eye, but more than 20% of asymptomatic COVID-19 patients have retinal microvasculopathy, with reduced blood vessel and blood flow density in the macula. There are also cases of acute macular neuroretinopathy.
[0028] A major problem with COVID-19 is that it compromises vascular health, which can affect blood flow throughout the body, with the very small microvessels, which have a relatively large vessel wall surface area, being most at risk. Summary of the Invention
[0029] As the long-term COVID problem is spreading and no effective treatment is available so far to improve the visual and cognitive limitations, the aim of the present invention is to provide a system that allows for improved or restores blood flow regulation in the eye, i.e. the brain, ultimately resulting in improved synchronization of functional connectivity networks in the brain.
[0030] In accordance with the present invention, it has been recognized that a system employing neuromodulation with non-invasive electrical brain stimulation would be useful in this regard.
[0031] According to the present invention, transorbital alternating current stimulation (tACS) is preferred. Such alternating current stimulation causes neurons to fire action potentials and improves blood flow. This dual effect results in partial restoration of disturbed neural networks in the brain, with clinically positive effects on vision. By using this system, persistent COVID symptoms can be alleviated. As little as 3-10 days of treatment with the system according to the present invention results in long-lasting restoration of visual field and cognitive function.
[0032] Systematized microcurrent therapy results in electrical current flow in the eye, optic nerve and frontal cortex, midbrain and brain stem of the brain.
[0033] This current flow improves neural synchronization and blood circulation: in the eyes and brain, it normalizes vascular regulation and oxygen supply to nerve cells that have been disrupted by COVID.
[0034] The system is used daily for longer periods, for example, 2 to 15 days.
[0035] The current application may use alternating current or alternatively direct current therapy.
[0036] For example, an alternating current with a difference of 10 Hz is used. The current intensity is variable and lies, for example, in the range of 200 to 1000 μA.
[0037] According to the invention, the current intensity is slowly increased or ramped up in steps depending on whether the respective patient perceives a visual impression in the form of a flashing light or the like.
[0038] The increment may be, for example, 100 μA.
[0039] The solution to the problem according to the invention is achieved by a system according to the features of claim 1, the dependent claims containing at least advantageous embodiments and further developments.
[0040] Thus, according to the present invention, the stimulation signal sequence is repeatedly provided for application until a detectable reduction in existing vascular dysregulation in the eye and brain is determined. Such a determination can be performed automatically using a recording of vascular dynamics in the retina together with corresponding data acquisition. For example, vascular dynamics in the retina can be determined before and after treatment using a dynamic vascular analyzer (DVA).
[0041] The analyzer quantifies the retinal vasodilation response by measuring vessel diameter before, during and after flicker light stimulation, which provides information about the condition of arterial and venous vessels.
[0042] Since the retina contains central nervous system tissue, i.e., brain-like neurons and blood vessels, such an analysis can be considered a biomarker of the brain's vascular health.
[0043] To measure vascular dynamics, the retina can be videotaped with a fundus camera in a given field of view.
[0044] The fundus camera is then connected to the analysis system described above.
[0045] The pupils are dilated to obtain a complete image of the patient's central retina.
[0046] In one example, the retina of each eye was imaged and video-recorded during a 5-6 minute session consisting of several measurement periods.
[0047] For example, the 52nd baseline measurement, three repetitions of a 10Hz flicker stimulation period measurement of 20 seconds each, and then the 82nd post-flicker period.
[0048] The three flicker stimulation periods are averaged. The videos are then analyzed for changes in vessel diameter over time to assess kinetics.
[0049] In healthy retina, flicker induces neuronal activation and subsequently causes vasodilation through a neurovascular coupling mechanism.
[0050] In addition to the DVA analysis program used, absolute vessel diameters are determined to prove the validity of the system.
[0051] As a result of practical application of the system according to the invention, the patient reported that his visual field was restored after treatment. Visual acuity measurements showed improvement in both eyes.
[0052] There was also improvement in almost all cognitive domains after using the system.
[0053] Overall, the system of the present invention allows the application of eye and brain neuromodulation in the context of short-term treatments to enhance attention, improve memory performance and restore speech comprehension, especially in patients with long COVID symptoms.
[0054] The use of the system improves blood flow and reduces vascular dysregulation, which leads to neuronal synchronization of the brain's functional connectivity networks and can demonstrate a corresponding improvement in the severity of cognitive symptoms in long-COVID patients.
[0055] Crucial for the success and acceptance of the system and the means available therein according to the invention is the use of an intuitive applicator, whereby an optimal stimulation signal sequence can be found in combination with a configuration for non-invasive determination of blood flow and oxygen saturation to the subject's skin and brain, resulting in the greatest increase in blood flow and the longest lasting after-effects, so that the increase in blood flow and neuronal activation continues for as long as possible after stimulation, which is a clear indicator of the desired success of the treatment.
[0056] The impulse generator for generating the stimulation signal sequence can be a single-channel or multi-channel stimulator that interacts with a data processing and control unit such that a patient-specific stimulation signal sequence is generated.
[0057] Temporal positioning allows for simultaneous stimulation of both eyes with just one channel, thereby reducing manufacturing costs of the stimulus generator and increasing efficacy and reliability, i.e., variability of success.
[0058] The optimal stimulation signal sequence can be determined during initial treatment under medical supervision and then saved and transferred to the patient on a patient memory card for home use. It is also possible to store the data directly in the applicator's memory unit.
[0059] The applicator is designed to be intuitive to use, especially after brief instructions for home use.
[0060] Since it has been shown that the treatment is particularly successful if the patient remains stress-free immediately before and during the treatment, the applicator in one embodiment of the invention comprises sound generation means, in particular in the form of earphones or headphones. On the one hand, these sound generation means can be used to inform the patient how to operate the applicator, which program to select, how long the treatment will last, etc. Furthermore, audio messages, audio sequences or music can be played to induce the desired relaxation response.
[0061] The applicator therefore comprises an electrode holder that can be individually adjusted to the shape of the head. Furthermore, the electrode is placed on the temple for optimal stimulation. This has the advantage that the current intensity of the pulse sequence can be reduced while still generating sufficient phosphenes. A NIR feedback system can be used to maximize the hemodynamic aftereffects during non-invasive eye and brain simulation.
[0062] Returning to the applicant, during the course of extensive research and study, it has been discovered that electrode placement plays a crucial role in successful stimulation of the visual system.
[0063] In this regard, the so-called F7-F8 arrangement according to the nomenclature of the EEG10-20 system in the area of the patient's temples is proposed. In such a configuration, intraocular phosphenes are recorded at extremely low currents in the range of less than 2 mA at alternating current frequencies in the range of 8-25 Hz. If the electrodes are placed in the F7-F8 area, the patient can close his eyes or keep them open in a dark room. Due to the way the electrodes are pasted or placed, there is no uncomfortable pressure in the eyelid area or on or under the eye.
[0064] The use of moistened electrodes and their placement in the F7-F8 area also produces a very comfortable cooling effect, which leads to stress relief, reducing skin resistance and also improving treatment success.
[0065] With the above in mind, the present invention relates to a system for localized activation of the human eye and brain to reorganize neuronal networks to enhance residual vision in existing visual field defects and improve blood circulation, in which a pulsed current therapy, in particular a non-invasive alternating current pulse therapy, is used.
[0066] The system consists of an applicator for inducing electrical current into the eye and brain, stimulating blood flow and activation of nerve cells, particularly retinal ganglion cells.
[0067] The system also includes an impulse generator for generating the electrical stimulation signal, and a data processing and control unit for providing a patient-specific stimulation signal sequence.
[0068] The applicator has at least two electrodes that can be attached to the subject's head in the manner described below.
[0069] The interchangeable stimulation electrodes are attached to the applicator so as to be placed to the left and right of the eye in the area of the patient's temples, ie the so-called F7-F8 area.
[0070] Furthermore, the applicator has at least one configuration for non-invasive determination of blood flow to the skin and to the brain and in particular for determination of oxygen saturation based on fNIR spectroscopy.
[0071] A NIR emitter and at least one associated NIR detector are positioned on the patient's head at a location separate from and apart from the stimulation electrodes.
[0072] NIR spectroscopic data may be recorded, particularly during pauses or at the end of the stimulation signal sequence, to determine times of sustained improvement in blood flow and / or oxygen saturation, and then updated to a data processing control unit via the system of the present invention.
[0073] As a further development, the applicator can be individually adapted to the shape of the patient's head, for which purpose known adjustment means are designed to fix the applicator to the frontal and occipital regions of the patient.
[0074] In one embodiment of the present invention, the applicator is designed as a ring or crown shaped structure that can be placed on the head and is provided with nasal bridge support and / or ear support and / or occipital support.
[0075] Additionally, receptacles for electronics and weight compensation may be provided at the occipital region. The electronics may include a battery or accumulator to allow the applicator to be used without an external cable for power.
[0076] In one embodiment, the stimulation electrodes are designed as dry or wet pad electrodes.
[0077] In the case of moisturized pad electrodes, electrolytes can be used as moisturizing solutions to reduce the contact resistance between the respective conductive components in the electrodes and the surface of the patient's skin. The lower the contact resistance, the lower the current that can be selected for the pulse sequence, without unpleasant effects in terms of the typical tingling sensation when the current is felt. If therapeutically advantageous, the applicator can be provided with fixing points, in particular clips, for attaching further electrodes, which can also apply current, in particular alternating current, to the area below the patient's eye.
[0078] At least one interface for wired or wireless data transmission is formed on or in the applicator.
[0079] In this way, the applicator can exchange information with a higher-level system via a so-called air interface, register the progress of the treatment period and the success of the treatment, and make this data available or transmit it to the attending physician for evaluation and further optimization of the treatment.
[0080] In certain embodiments, sound generating means, in particular designed as earphones or headphones, are provided on the applicator in order to guide the patient during the treatment, in particular for the handling of the applicator and / or to acoustically relax the patient.
[0081] For self-sufficient operation, the applicator comprises both an impulse generator, in particular an AC impulse generator, and a data processing control unit together with a power supply, and the treatment and / or stimulation signal sequences can be realized by a computer program product. In this respect, the applicator therefore has all the necessary technical means for use and operation. It is therefore no longer necessary to provide a separate impulse generating unit that must be wired to or held by the patient, as is realized in the known prior art, for example, by devices fastened to the patient's belt or held in the patient's pocket.
[0082] An electrolyte reservoir for electrode wetting can be provided on or within the applicator, allowing the patient to slightly moisten the electrodes themselves if they begin to dry out. Alternatively, the electrolyte supply can be automatically controlled by a suitable sensor via a tube communicating with the electrode holder.
[0083] In a further embodiment, the applicator and / or the receptacle for holding the electrodes consists of a malleable plastic material, which allows the applicator to be individually adapted to the particular head shape, in particular to the forehead, nose or neck area of the patient, thereby providing a real individualization for the patient concerned.
[0084] The holder and / or the stimulation electrodes may be constructed from a conductive plastic material, thereby simplifying the construction of the applicator and enabling the transmission of power or stimulation pulse sequences via such conductive material.
[0085] It is within the scope of the present invention that a pocket or similar holder for a replacement electrode is provided on the applicator. If a replaceable electrode is lost, treatment can be continued, which is particularly advantageous when the patient being treated is not otherwise near the medical practice that cares for him.
[0086] For particularly stationary or clinical applications, the applicator may be combined with a known EEG electrode cap.
[0087] As already indicated, the applicator may have a unit for determining the contact resistance between the stimulation electrode and the patient's skin surface in order to switch off the impulse generator or reduce the current flow if the contact resistance is abnormal, in particular if it is too high.
[0088] The invention will now be explained in more detail with reference to exemplary embodiments and with the aid of the drawings. [Brief description of the drawings]
[0089] [Figure 1] FIG. 1 shows a front view of a typical elongated COVID applicator that is attached to a subject's head. [Diagram 2] 1 shows a rear view of the applicator looking at the back of a subject's head. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0090] The applicator 1 according to figures 1 and 2 consists of a base body 2 made at least partly from an elastic material and can be individually adapted to the head shape of a designated subject 3.
[0091] The base body 2 is realised as a ring-like or crown-like structure that can be placed on the head of the subject 3, with a nasal bridge support 4 including adjustment options to suit the anatomical condition.
[0092] The base body 2 is also connected to ear supports 5 for the left and right ears 6 of the subject 3 .
[0093] At the back of the head, the base body 2 is provided with a holder for electronic components.
[0094] On the one hand, this can be a memory unit 7 containing a stimulation program. Furthermore, an impulse generator for generating electrical stimulation signals together with a control unit for providing patient-specific stimulation signal sequences can be housed or attached, preferably at this occipital site.
[0095] The interface 8, designed for example as a USB port, can be used not only for data transmission but also for charging a secondary battery 9 in order to power the necessary electrical or electronic components.
[0096] Such a secondary battery 9 can for example be a replaceable lithium battery housed in a corresponding recess in the base body 2 .
[0097] Stimulating electrodes 10 are interchangeably attached to the base body 2 and are positioned to rest or abut to the left and right of the eye in the temple region of the patient's head as shown.
[0098] In the front area of the base body 2 there is an adjustment device 12 in which a labelling field 11 can be provided to create a space for a company logo, an instruction manual or for attaching a user name or user identification information.
[0099] Sensors 13 may be attached to or embedded in the base body 2 to perform non-invasive determination of blood flow to the skin and brain and to determine oxygen saturation. These sensors are located remotely from the stimulation electrodes 10.
Claims
1. 1. A system for activating neurons in a human eye and brain to enhance residual vision in the presence of visual field defects, or to alleviate or correct other visual or cognitive deficits, by neurostimulation, particularly non-invasive application of microcurrents to the head, more particularly non-invasive alternating current pulse stimulation (tACS), comprising: a non-invasive applicator for inducing energy flow to the eye and brain, stimulating blood flow and activating neural cells, particularly retinal ganglion and brain cells; an impulse generator for generating an electrical or magnetic stimulation signal; a data processing and control unit for providing a patient-specific stimulation signal sequence; The applicator comprises, for example, at least two electrodes that can be brought into contact with the subject's head, in which stimulation electrodes, in particular replaceable electrodes, are fixed to the applicator so as to rest or abut on the left and right of the eye in the region of the temples of the patient's head; The system wherein the stimulation signal sequence is repeatedly provided for application until a detectable reduction in existing vascular dysregulation in the eye and brain is determined.
2. System according to claim 1, characterized in its use and application for the alleviation of functional long-term pathologies resulting from diseases of viral origin, in particular diseases associated with the SARS-COV-2 virus.
3. 3. The system according to claim 1 or 2, characterized in that the applicator can be individually adapted to the shape of the patient's head, for this purpose adjustment means are provided for fixation to the frontal and occipital regions of the patient's head.
4. 4. The system according to claim 1, 2 or 3, characterized in that the applicator is designed as a ring or crown shaped structure that can be placed on the head, with nasal bridge support and / or ear support and / or occipital support, as well as receptacles for electronic components and for weight compensation, provided in the occipital region.
5. 5. A system according to claim 1, characterized in that fixing points are provided on the applicator for attaching, in particular for clipping, further electrodes which also enable the application of an alternating current to the area below the patient's eye.
6. A system according to any one of claims 1 to 5, characterized in that an interface for wired or wireless data transmission is formed on or in the applicator.
7. System according to any one of claims 1 to 6, characterised in that sound generation means, in particular designed as earphones or headphones, are provided on the applicator in order to guide the patient with information and / or acoustically relax the patient during the alternating current pulse treatment, and further capable of supplying heat, in particular infrared radiant heat, to the patient in the application area.
8. A system according to any one of claims 1 to 7, characterized in that for self-sufficient operation, the applicator comprises both an AC impulse generator and the data processing control unit together with a power source, and that treatment sequences and / or the stimulation signal sequences can be realised by a computer program product.
9. 9. The system according to claim 1, characterized in that the unit for determining the contact resistance between the stimulation electrode and the patient's skin surface is designed to switch off the impulse generator in case of an abnormal, in particular excessive, resistance.
10. the applicator comprises at least one arrangement for non-invasive determination of blood flow to the skin and to the brain and in particular for determination of oxygen saturation based on fNIR spectroscopy, the NIR emitter and at least one associated NIR detector are positionable on the patient's head at a location separate from and apart from the stimulation electrode; A system according to any one of claims 1 to 9, characterized in that NIR spectroscopic data is recorded, in particular during a pause or at the end of a stimulation signal sequence, in order to determine the time of sustained improvement in blood flow and / or oxygen saturation, whereby an update operation of the data processing control unit can be subsequently realized.
11. A system according to any one of claims 1 to 10, characterized in that the positions of the stimulation electrodes correspond to the F7-F8 configuration according to the nomenclature of the EEG 10-20 system.
12. A system according to any one of claims 1 to 11, characterized in that in the preferred case of microcurrent application, the current intensity of the stimulation signal is increased stepwise according to a predefined morphology, in particular depending on a visual impression such as a flash of light, and / or the stimulation parameters are adjusted or fixed depending on the dilation capacity of the eye's blood vessels.
Citation Information
Patent Citations
Therapeutic apparatus
JP1993031197A
Method for measuring frequency of electromagnetic wave and method for killing and eliminating microbe or the like
JP2000245813A
Regulation of function related to nerve structures near the ear
JP2015500092A
Systems and methods for non-invasive neural stimulation
JP2016530017A
Head worn apparatuses for vision therapy
US20200171307A1
